Advertisement

Topics

Roche's Tecentriq hits trouble with NICE in bladder cancer

07:52 EDT 3 Aug 2017 | pharmaphorum

NICE has said Roche’s cancer immunotherapy Tecentriq (atezolizumab) should not receive regulatory NHS funding as a treatment for bladder cancer in first draft guidance, although there is a chance it could be cost-effective as a first-line therapy. ...

Original Article: Roche's Tecentriq hits trouble with NICE in bladder cancer

NEXT ARTICLE

More From BioPortfolio on "Roche's Tecentriq hits trouble with NICE in bladder cancer"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...